// App-Quantinova.ai

: Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)

Researchers

Presenter

  • Christopher P. Denton

Principal Investigators

  • Jonathan Goldin

  • Grace Kim

  • Masataka Kuwana

  • Yannick Allanore

  • Anastas Batalov

  • Irena Butrimiene

  • Patricia Carreira

  • Marco Matucci-Cerinic

  • Oliver Distler

  • Duanka Martinovic Kaliterna

  • Carmen-Marina Mihai

  • Mette Mogensen

  • Marzena Olesinska

  • Janet E. Pope

  • Gabriela Riemekasten

  • Tatiana Sofa Rodriguez-Reyne

  • Maria Jos Santos

  • Jacob Van Laar

  • Helen Spotswood

  • Jeffrey Siegel

  • Angelika Jahreis

  • Daniel E. Furst

  • Dinesh Khanna

Medical Centers

  • Kings College London, London, United Kingdom

  • Genentech, Inc., South San Francisco, California, United States of America

  • University of California Los Angeles - Los Angeles - United States of America

  • Nippon Medical School, Tokyo, Japan

  • Paris Descartes University, Paris, France

  • Medical University Plovdiv, Plovdiv, Bulgaria

  • Rheumatology Clinic, Medical Faculty, Vilnius University, Vilnius, Lithuania,

  • Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain

  • University of Florence, Florence, Italy

  • University of Zurich Hospital, Zurich, Switzerland

  • University Hospital Split, Split, Croatia

  • Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania,

  • Bispebjerg Hospital, Department of Dermatology, Copenhagen, Denmark

  • National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland

  • University of Western Ontario, St Joseph's Health Care, London,Canada

  • University of Lubek and Charite University Hospital, Berlin, Germany,

  • Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

  • Hospital Garcia de Orta, Almada, Portugal

  • University Medical Center Utrecht, Utrecht, Netherlands

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • University of Michigan - Ann Arbor - United States of America

Locations

  • United Kingdom

  • United States

  • Japan

  • France

  • Bulgaria

  • Lithuania

  • Spain

  • Italy

  • Switzerland

  • Croatia

  • Romania

  • Denmark

  • Poland

  • Canada

  • Germany

  • Mexico

  • Portugal

  • Netherlands

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • Scleroderma

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved